tiprankstipranks
Trending News
More News >

CERo Therapeutics Completes Additional Series D Funding

Story Highlights
  • CERo Therapeutics Holdings sold Series D Preferred Stock convertible into common stock.
  • On June 25, 2025, the company raised $1,852,000 from an additional closing of Series D shares.
  • Looking for the best stocks to buy? Follow the recommendations of top-performing analysts.
CERo Therapeutics Completes Additional Series D Funding

Don’t Miss TipRanks’ Half-Year Sale

The latest announcement is out from CERo Therapeutics Holdings ( (CERO) ).

CERo Therapeutics Holdings recently engaged in a private placement offering, selling shares of its Series D Preferred Stock, which are convertible into common stock. On June 25, 2025, the company completed an additional closing, raising approximately $1,852,000 from the sale of 2,315 shares. This transaction was conducted without registration under the Securities Act, relying on exemptions for sales to accredited investors, potentially impacting the company’s capital structure and financial flexibility.

The most recent analyst rating on (CERO) stock is a Buy with a $3.00 price target. To see the full list of analyst forecasts on CERo Therapeutics Holdings stock, see the CERO Stock Forecast page.

More about CERo Therapeutics Holdings

Average Trading Volume: 1,161,738

Technical Sentiment Signal: Sell

Current Market Cap: $4.93M

For a thorough assessment of CERO stock, go to TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1